Primary Generalized Epilepsy

Neurology
3
Pipeline Programs
1
Companies
1
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
CENOBAMATEApproved
cenobamate
Unknown Company
SK Life Science
XCOPRIApproved
cenobamate
SK Life Science
oral2019

Competitive Landscape

1 companies ranked by most advanced pipeline stage

SK Life Science
SK Life ScienceNJ - Paramus
1 program
1
1
CenobamatePhase 31 trial
Active Trials
NCT03678753CompletedEst. May 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SK Life ScienceCenobamate

Clinical Trials (1)

NCT03678753SK Life ScienceCenobamate

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

Start: Sep 2018Est. completion: May 2025
Phase 3Completed

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
11h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
11h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
12h ago

Director of Finance

CoMind
London, UK
12h ago

Electronics Engineering Manager

CoMind
London, UK
12h ago

Director of Information Technology

Zavation Medical Products
12h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)